Solid tumour therapeutic - Swarm Oncology
Latest Information Update: 07 Oct 2025
At a glance
- Originator Swarm Oncology
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 31 Jul 2025 Preclinical trials in Solid tumours in United Kingdom (unspecified route) before July 2025 (Swarm Oncology pipeline, July 2025)